Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Cash from Investing Activities (2023 - 2025)

Historic Cash from Investing Activities for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to -$7000.0.

  • Inhibrx Biosciences' Cash from Investing Activities rose 9716.6% to -$7000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$44000.0, marking a year-over-year increase of 9926.95%. This contributed to the annual value of -$2.6 million for FY2024, which is 4345.74% up from last year.
  • Latest data reveals that Inhibrx Biosciences reported Cash from Investing Activities of -$7000.0 as of Q3 2025, which was up 9716.6% from -$21000.0 recorded in Q1 2025.
  • In the past 5 years, Inhibrx Biosciences' Cash from Investing Activities ranged from a high of -$7000.0 in Q3 2025 and a low of -$3.4 million during Q4 2023
  • Moreover, its 3-year median value for Cash from Investing Activities was -$529000.0 (2023), whereas its average is -$859750.0.
  • Data for Inhibrx Biosciences' Cash from Investing Activities shows a peak YoY increase of 9953.52% (in 2024) and a maximum YoY decrease of 6954.38% (in 2024) over the last 5 years.
  • Over the past 3 years, Inhibrx Biosciences' Cash from Investing Activities (Quarter) stood at -$3.4 million in 2023, then surged by 99.54% to -$16000.0 in 2024, then skyrocketed by 56.25% to -$7000.0 in 2025.
  • Its Cash from Investing Activities was -$7000.0 in Q3 2025, compared to -$21000.0 in Q1 2025 and -$16000.0 in Q4 2024.